MiraDx

MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer. MiraDx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D. whose cutting-edge genetic research discovered this new class of genetic biomarkers. Our cutting-edge genetic research discovered a new class of genetic biomarkers that can dramatically change personalized treatment. Improve assessment of individual patient’s responses and toxicity profiles to specific therapies, to radically change the meaning of personalized medicine.